BioSpace News Archive

Hilltop BioSciences, a veterinary biotech company pioneering the development of innovative regenerative therapies, will be introducing several new formulations at VMX in Orlando where they will be showcased in the Startup Circle (Booth s5027).

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at PepTalk occurring January 16-22, 2023 in San Diego, CA.

First-of-its-kind technology stack in autoimmune diseases. Provides unprecedented insights into optimal patient treatment pathway.

NKGen Biotech today announced the appointment of Paul Y. Song, MD as Chief Executive Officer (CEO) and Vice Chairman of the Board of Directors, effective January 10, 2023.

On January 9 th 2023, CRISPR QC has announced that they have closed their Seed Round at $1.6M and appoints George Bonaros to Board of Directors to fuel commercial growth of their CRISPR Analytics Platform.

Gemina Laboratories Ltd. is pleased to provide the following strategic overview and share an outlook for 2023 and beyond.

Avadel Pharmaceuticals plc today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase an aggregate of 105,000 ordinary shares under Avadel’s 2021 Inducement Plan.

Armata Pharmaceuticals, Inc. today announced that it has closed a secured convertible credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, “Innoviva”), Armata’s largest shareholder.

Glaukos Corporation today announced positive results for a prospective, multi-center clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose® TR (travoprost intraocular implant) in subjects who had previously been administered an iDose TR in the Phase 2b clinical trial (referred to as the “exchange trial”).

Glaukos Corporation today announced positive clinical updates for several of its Corneal Health pipeline programs, including the commencement of subject enrollment in a second Phase 3 confirmatory trial for Epioxa™ (Epi-on™), and promising initial results from the company’s Phase 2a clinical trial for GLK-301 (iLution - Dry Eye Disease).